Who is sponsoring NCT02822742?

NCT02822742 is sponsored by Santen Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02822742?

Interventions in NCT02822742: DE-117 ophthalmic solution, Latanoprost ophthalmic solution 0.005%.

What condition does NCT02822742 study?

NCT02822742 studies Primary Open Angle Glaucoma or Ocular Hypertension.

Is NCT02822742 still recruiting?

NCT02822742 is currently completed. Last updated 20 November 2017.

Last reviewed 2017-11-20 · How we verify

NCT02822742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Completed Phase 3 Last updated 20 November 2017

What this trial tests

Phase 3 trial testing DE-117 ophthalmic solution in Primary Open Angle Glaucoma or Ocular Hypertension in 26 participants. Completed in 28 April 2017.

Timeline

2 July 2016

Primary endpoint
28 April 2017

28 April 2017

Quick facts

Lead sponsor	Santen Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	2 July 2016
Primary completion	28 April 2017
Estimated completion	28 April 2017
Sites	1 location across Japan

Drugs / interventions tested

DE-117 ophthalmic solution — full drug profile →
Latanoprost ophthalmic solution 0.005% — full drug profile →

Conditions studied

Primary Open Angle Glaucoma or Ocular Hypertension — all drugs for Primary Open Angle Glaucoma or Ocular Hypertension →

Sponsor

Santen Pharmaceutical Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Primary Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M, Ropo A, Lu F, Kawata H, et al · · 2020 · cited 40× · PMID 32572719 · DOI 10.1007/s10384-020-00748-x
Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Matsuo M, Matsuoka Y, Tanito M. · · 2022 · cited 23× · PMID 35510270 · DOI 10.2147/opth.s340386
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.
Sharif NA. · · 2023 · cited 5× · PMID 37375739 · DOI 10.3390/ph16060791

Verify or expand the search:

Other recruiting trials for Primary Open Angle Glaucoma or Ocular Hypertension

Currently open trials in the same condition.

NCT06865144 — Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Po · Phase 4 · recruiting
NCT07076303 — A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Press · recruiting

Other Santen Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06911216 — A Pharmacokinetics (PK) Study in Healthy Adults · EARLY_PHASE1 · completed
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT05905653 — Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers · Phase 1 · completed
NCT05495061 — A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension · Phase 3 · completed
NCT05503901 — A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02822742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Santen Pharmaceutical Co., Ltd.
Last refreshed: 20 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02822742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing